Metabolite, immunocyte phenotype, and lymphoma: a Mendelian randomization study
Chenyang Fan1, Pengying Yuan2, Xiangdong Yang1
1First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, National Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.
Frontiers in Immunology
|October 10, 2024
Summary
This study reveals bidirectional causal links between metabolites, immune cell phenotypes, and lymphoma risk. While immune cells partially mediate some metabolite-lymphoma associations, most mediating factors remain unknown.
Area of Science:
- Metabolomics
- Immunology
- Oncology
- Genetic Epidemiology
Background:
- Metabolites and immunocyte phenotypes are linked to lymphoma risk.
- The bidirectional causality and mediating roles of immunity in metabolism-lymphoma relationships are unclear.
Purpose of the Study:
- To investigate the causal relationships between metabolites, immune cell phenotypes, and lymphoma.
- To determine if immune cell phenotypes mediate the effect of metabolites on lymphoma risk.
Main Methods:
- Two-sample Mendelian randomization (MR) and two-step MR analyses were employed.
- Large-scale genome-wide association studies (GWAS) data for 1400 metabolites, 731 immunocyte phenotypes, and eight lymphoma subtypes were utilized.
Main Results:
- Bidirectional causal relationships were found between 17 metabolites and lymphoma, and 12 immunocyte phenotypes and lymphoma.
- Immune cell phenotypes mediated three metabolite-lymphoma associations, including the role of CD27+ plasmablasts/plasma cells in the arginine to glutamate ratio's association with chronic lymphocytic leukemia.
Conclusions:
- A causal relationship exists between metabolites and lymphoma, with immune cell phenotypes playing a minor mediating role.
- Further research is needed to identify the primary mediators of metabolite effects on lymphoma development.
